The study published in CNS Drugs evaluated the safety profile of TV-46000, a long-acting risperidone injection, for the treatment of schizophrenia in adults. The study found that rates of adverse events were similar in both dosing groups, adding to the consistent and favorable safety profile of TV-46000. The SHINE study, conducted by Christoph Correll and colleagues, included 336 patients with stable schizophrenia who completed the RISE study without relapse. Overall, the findings confirmed the long-term safety and tolerability of TV-46000, with injection site pain and injection site nodule being frequent treatment-related adverse events. The study was funded by Teva Pharmaceuticals.
Source link
Safety of TV-46000, long-acting injection for schizophrenia, consistent in phase 3 study
